Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Chinese ephedra regs

This article was originally published in The Tan Sheet

Executive Summary

Chinese ephedra regs: China does not permit ephedra as a single component in traditional medicine preparations, Mei-Ling Hsiao, director of the China Health Department's Bureau of Pharmaceutical Affairs, tells FDA in an Aug. 23 letter. Hsiao also notes that products containing the herb may not be sold as dietary supplements and may not contain over 15 mg of the substance. In similar letters, Japan, Britain, Sweden, Australia, and the Ukraine all informed FDA that ephedra-containing products must be sold as drugs in their respective countries. FDA had asked for information on the "regulation/approval/registration" status of the herb in a number of countries...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel